AVITA Medical to Present at Upcoming Investor Conferences
17 November 2021 - 8:01AM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative
medicine company that is developing and commercializing a
technology platform that enables point-of-care autologous skin
restoration for multiple unmet needs, announced today that its
management will present at the following upcoming investor
conferences:
- Canaccord Genuity MedTech, Diagnostics and Digital Health &
Services ForumPresenting on Thursday, November 18, 2021 at 10:30
a.m. Eastern Standard Time (Friday, November 19, 2021 at 1:30 a.m.
Australian Eastern Standard Time). A live webcast of the
presentation may be accessed here.
- 33rd Annual Piper Sandler Virtual Healthcare
ConferenceParticipating on Thursday, December 2, 2021 (Friday,
December 3, 2021 Australian Eastern Standard Time). The fireside
chat will be available starting Monday, November 22, 2021 (Tuesday,
November 23, 2021 Australian Eastern Standard Time). The webcast
may be accessed by visiting ir.avitamedical.com under the
“Events & Presentation” section.The replays will be available
shortly after the conclusion of the presentations and will be
archived on AVITA Medical’s website for 90 days.
Authorized for release by the Chief Financial Officer of AVITA
Medical, Inc.
ABOUT AVITA MEDICAL, INC.AVITA Medical, Inc. is
a regenerative medicine company with a technology platform
positioned to address unmet medical needs in burns, chronic wounds,
and aesthetics indications. AVITA Medical Inc. patented and
proprietary collection and application technology provides
innovative treatment solutions derived from the regenerative
properties of a patient’s own skin. The medical devices work by
preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous
suspension comprised of the patient’s skin cells necessary to
regenerate natural healthy epidermis. This autologous suspension is
then sprayed onto the areas of the patient requiring treatment.
AVITA Medicals’ first U.S. product, the RECELL® System, was
approved by the U.S. Food and Drug Administration (FDA) in
September 2018. The RECELL® System is approved for acute
partial-thickness thermal burn wounds in patients 18 years of age
and older or application in combination with meshed autografting
for acute full-thickness thermal burn wounds in pediatric and adult
patients. The RECELL® System is used to prepare Spray-On Skin™
Cells using a small amount of a patient’s own skin, providing a new
way to treat severe burns, while significantly reducing the amount
of donor skin required. The RECELL® System is designed to be used
at the point of care alone or in combination with autografts
depending on the depth of the burn injury. Compelling data from
randomized, controlled clinical trials conducted at major U.S. burn
centers and real-world use in more than 8,000 patients globally,
reinforce that the RECELL® System is a significant advancement over
the current standard of care for burn patients and offers benefits
in clinical outcomes and cost savings. Healthcare professionals
should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell
Harvesting Device (https://recellsystem.com/) for a full
description of indications for use and important safety information
including contraindications, warnings, and precautions.
In international markets, our products are marketed under the
RECELL® System brand to promote skin healing in a wide range of
applications including burns, chronic wounds, and aesthetics. The
RECELL® System is TGA-registered in Australia and received CE-mark
approval in Europe.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,”
“will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
other words of similar meaning and the use of future dates.
Forward-looking statements in this press release include, but are
not limited to, statements concerning, among other things, our
ongoing clinical trials and product development activities,
regulatory approval of our products, the potential for future
growth in our business, and our ability to achieve our key
strategic, operational and financial goal. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Each forward-looking statement contained in
this press release is subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statement. Applicable risks and uncertainties
include, among others, the timing of regulatory approvals of our
products; physician acceptance, endorsement, and use of our
products; failure to achieve the anticipated benefits from approval
of our products; the effect of regulatory actions; product
liability claims; risks associated with international operations
and expansion; and other business effects, including the effects of
industry, economic or political conditions outside of the company’s
control. Investors should not place considerable reliance on the
forward-looking statements contained in this press release.
Investors are encouraged to read our publicly available filings for
a discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of
the date of this release, and we undertake no obligation to update
or revise any of these statements.
This press release was authorized by the review committee of
AVITA Medical, Inc.
FOR FURTHER INFORMATION:
U.S. MediaSam Brown, Inc.Christy CurranPhone
+1-615-414-8668christycurran@sambrown.comO.U.S.
MediaRudi Michelson Phone +61 (0)3 9620 3333 Mobile +61
(0)411 402 737 rudim@monsoon.com.au |
InvestorsICR WestwickeCaroline CornerPhone
+1-415-202-5678 caroline.corner@westwicke.com |
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024